WCG Wealth Advisors LLC grew its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 12.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,245 shares of the company’s stock after acquiring an additional 3,790 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Sanofi were worth $1,662,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Altrius Capital Management Inc increased its holdings in shares of Sanofi by 1.1% during the second quarter. Altrius Capital Management Inc now owns 160,733 shares of the company’s stock worth $7,799,000 after buying an additional 1,685 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Sanofi by 9.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 308,282 shares of the company’s stock worth $14,958,000 after purchasing an additional 26,375 shares in the last quarter. Hsbc Holdings PLC raised its position in Sanofi by 2,735.8% in the second quarter. Hsbc Holdings PLC now owns 279,981 shares of the company’s stock valued at $13,661,000 after purchasing an additional 270,108 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Sanofi by 21.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 63,593 shares of the company’s stock valued at $3,044,000 after purchasing an additional 11,404 shares in the last quarter. Finally, Argent Trust Co grew its holdings in shares of Sanofi by 11.7% during the second quarter. Argent Trust Co now owns 23,594 shares of the company’s stock worth $1,145,000 after purchasing an additional 2,478 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.
Sanofi Stock Performance
NASDAQ:SNY opened at $58.26 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The company has a 50 day simple moving average of $54.08 and a two-hundred day simple moving average of $50.35. The company has a market capitalization of $147.56 billion, a PE ratio of 29.28, a P/E/G ratio of 1.62 and a beta of 0.60.
Analysts Set New Price Targets
A number of research analysts recently issued reports on SNY shares. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday. Finally, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $57.50.
Read Our Latest Report on Sanofi
Sanofi Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
- Five stocks we like better than Sanofi
- What is a support level?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Canadian Penny Stocks: Can They Make You Rich?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Find and Profitably Trade Stocks at 52-Week Lows
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.